Gilead's Covid-19 cure trial may yield results ahead of schedule: Report

In the absence of hard evidence, US medical associations and the National Institutes of Health have not recommended remdesivir for treatment of Covid-19 so far

A key US government trial of Gilead Sciences Inc's experimental coronavirus treatment may yield results as early as mid-May, according to the study's lead investigator, after doctors clamoured to enrol their patients in the study.

Preliminary findings from the randomised trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr Andre Kalil told Reuters in an interview.

There are currently no approved treatments or vaccines for Covid-19, the respiratory illness caused by the new virus that has killed over 190,000 people globally, according to